Lack of relationship between blood glucose-lowering activity of colestimide and serum cholecystokinin (CCK) concentrations in patients with type 2 diabetes

Journal of Nippon Medical School

Volumn 75, Issue 2, 2008, Pages 111-115

  Suzuki, Tatsuya ^a   Oba, Kenzo ^a   Norose, Jun ^a   Yoshimatsu, Hiroomi ^a   Sekimizu, Kenichi ^a   Futami Suda, Shoko ^a   Ouchi, Motoshi ^a   Suzuki, Kazunari ^a   Kigawa, Yoshiaki ^b   Nakano, Hiroshi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Hanno Geriatric Hospital   (Japan)

Author keywords

Cholecystokinin; Colestimide; Plasma glucose; Type 2 diabetes mellitus

Indexed keywords

CHOLECYSTOKININ; COLESTILAN; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; IMMUNOREACTIVE INSULIN; LIPID; PIOGLITAZONE;

AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; ANION EXCHANGE RESINS; BLOOD GLUCOSE; CHOLECYSTOKININ; DIABETES MELLITUS, TYPE 2; EPICHLOROHYDRIN; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; IMIDAZOLES; MALE; RESINS, SYNTHETIC;

EID: 42049104933     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.75.111     Document Type: Article

References (22)

1. Suzuki T, Oba K, Futami S, et al: Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: A case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006; 73: 277-284.
2. Yamakawa T, Takano T, Utsunomiya H, Kadonosono K, Okamura A: Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endcr J 2007; 54: 53-58.
3. Bloomgarden ZT: Achieving glycemic goals in type 2 diabetes. Diabetes Care 2007; 30: 174-184
4. Watanabe M, Houten SM, Mataki C, et al: Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-489.
5. Kajiyama G, Tazuma S, Yamashita G, et al: Effect of MCI-196 on biliary lipids metabolism in patients with hypercholesterolemia. J Clin Ther Med 1996; 12: 1349-1359.
6. Suzuki T, Oba K, Igari Y, et al.: Colestimide lowers plasma glucose levels and increases plasma glucagon-like peptide-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hyperlipidemia. J Nippon Med Sch 2007 (In press).
7. Ahren B, Holst JJ, Efendic S: Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endoclinol Metab 2000; 85: 1043-1048.
8. Rushakoff RA, Goldfine ID, Beccaria LJ, Mathur A, Brand RJ, Liddle RA: Reduced postprandial cholecystokinin (CCK) secretion in patients with non-insulin-dependent diabetes mellitus: evidence for a role CCK in regulating postprandial hyperglycemia. J Clin Endocrinol Metab 1993; 76: 489-493.
9. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA: Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 1985; 75: 1144-1152.
10. Kogire M, Gomez G, Uchida T, Ishizuka J, Greedley GH Jr, Thompson JC: Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats. Pancreas 1992; 7: 15-20.
11. Gomez G, Upp JR Jr, Lluis F, et al.: Regulation of the release of cholecystokinin by bile salts in dogs and human. Gastroenterology 1988; 94: 1036-1046.
12. Gomez G, Townsend CM Jr, Maani R, Singh P, Greeley GH Jr, Thompson JC: Down regulation of pancreatic growth and gallbladder contractility by bile salts. Am J Surg 1989; 157: 20-26.
13. Karlsson S, Ahren B: Cholecystokinin-stimulated insulin secretion and protein kinase C in rat pancreatic islets. Acta Physiol Scand 1991; 142: 397-403.
14. Ahren B, Martensson H, Nobin: A Cholecystokinin (CCK)-4 and CCK-8 stimulate islet hormones secretion in vivo in the pig. Pancreas 1988; 3: 279-284.
15. Liddle RA, Gerts BJ, Kanayama S, et al.: Regulation of pancreatic endocrine function by cholecystokinin: Studies with MK-329, a nonpeptide cholecystokinin receptor antagonist. J Clin Endoclinol Metab 1990; 70: 1312-1318.
16. Ahren B, Pettersson M, Uvans-Moberg K, Gutniak M: Efendic S Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide on basal and meal-stimulated pancreatic hormone secretion in man. Diabetes Res Clin Pract 1991; 13: 153-162.
17. Reimers J, Nauk M, Creutzfeldt W, et al.: Lack of insulinotropic effect of endogenous and exogenous cholecystokinin in man. Diabetologia 1988; 31: 271-280.
18. Fieseler P, Bridenbaugh S, Nustede R, et al.: Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-1 but not by CCK-8. Am J Physiol 1995; 268: E949-E955.
19. Rushakoff RJ, Goldfine ID, Carter JD, Liddle RA: Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans. J Clin Endocrinol Metab 1987; 65: 395-401.
20. Hashim SA, Bergen SS Jr, Van Itallie TB: Experimental steatorrhea induced in man by bile acid sequestrant. Proc Soc Exp Biol Med 1961; 173-175.
21. Thompson AB, Keelan M: Feeding rats diets containing choeno- or ursodeoxycholic acid or cholestyramine modifies intestinal uptake of glucose and lipids. Digestion 1987; 38: 160-170.
22. Cariou B, Duran-Sanoval D, Kuipers F, Staels B: Farnesoid receptor X: a new player in glucose metabolism? Endocrinology 2005; 146: 981-983.